Novartis relates arroyo autographed baseball (NOVN.VX), meanwhile, baseball tickets conclude is committed to buying eyecare giant Alcon (ACL.N).With strong cash positions, Sanofi and Glaxo could both contemplate similar large-scale transactions as a tactic to deal with stalling sales growth, looming U.S. healthcare reform and loss of patent protection on many blockbuster medicines.Yet Witty has flatly ruled out a mega-deal and Viehbacher, while not closing the door on the idea completely, wants to focus on small and mid-sized deals up to around 15 billion euros in generics, emerging markets, vaccines, consumer health and biotech."Sanofi is looking at everything but Viehbacher will be very cautious. He doesn't want to repeat the mistake of (AstraZeneca CEO David) Brennan when he overpaid for MedImmune," said one healthcare banker familiar with the group."Is he going to bid a big premium on a $50-billion-plus asset? I don't think so."BUYING TIMEViehbacher knows Sanofi needs to change and he has been holding its feet to the fire, shaping the French drugmaker from an introverted company into one with a more open and diversified approach that should secure better long-term growth.He estimates Sanofi is "about half way through" the transformation process. The next step will come with a restructuring of drug research, due in weeks.For 2009 Sanofi has suggested, and analysts expect, that EPS could beat its 7 percent growth goal at constant exchange rates. Beyond, many analysts see EPS declining until 2013, as more than a fifth of its current drug sales face patent loss, unless it cuts spending aggressively or makes a major takeover."They need to fix the mismatch between pipeline potential and generic overhang in pharmaceuticals. To buy time they need to acquire and do as many biotech partnerships as they can to rebuild their pipeline," said Helvea analyst Karl Heinz Koch.So far, Viehbacher has picked up two Latin American generic businesses to boost Sanofi's emerging markets presence, as well a promising privately owned cancer company, BiPar Sciences.One large and obvious bid target is Bristol-Myers Squibb (BMY.N), Sanofi's long-time U.S.
partner on blood thinner Plavix, but Viehbacher said in March he was happy with existing partnership arrangements.Another could be Amgen (AMGN.O), although recent speculation in the French media that Sanofi had been working on such a large deal, only to have it turned down by its largest shareholders, was formally denied by Sanofi two weeks ago.The latest rumor is Anglo-Swedish drugmaker AstraZeneca (AZN.L) -- an even bigger bite than Bristol or Amgen, with a market value of around $65 billion -- which Kepler analyst Tero Weckroth said looked "very unlikely."CREDIT RATINGBankers said a desire at Sanofi to retain its investment-grade credit rating was a factor behind the cautious approach for the time being.One smaller-scale deal, however, may be a no-brainer baseball . Sanofi could well snatch the other half of animal health company Merial from its joint-venture partner Merck, which must reduce its vet business to win clearance to buy Schering-Plough SGP.N.Over at Glaxo, Witty is ready to get his wallet out when necessary, agreeing to pay up to $3.6 billion for dermatology company Stiefel in an auction that, ironically, was initiated by interest from Sanofi, according to banking sources.Many of Witty's more recent deals, however, have been collaborations, often involving no upfront cash brandon phillips jerseys . Examples include an unusual tie-up with Pfizer on HIV medicine, a assets-for-equity swap with South Africa's Aspen (APNJ.J) and an emerging markets distribution deal with Dr Reddy's (REDY.BO)."Those more creative options have become the order of the day," Witty told a healthcare conference last week.The approach is winning support from investors like Liontrust fund manager Anthony Cross, who is skeptical about traditional large-scale acquisitions and believes Witty has found a better way to leverage Glaxo's distribution network."A lot of the previous mega-mergers have not necessarily been huge value creators and this is a lower risk way," he said.(Editing by Sitaraman Shankar) Deals cincinatti baseball . LONDON (Reuters) - The history of past drug scares suggests concerns over the safety of Sanofi-Aventis's (SASY.PA) diabetes treatment Lantus will hit sales, whether or not a suggested link to cancer proves real cincinatti red baseball . Food and Drug Administration review documents dating back to 2000 mentioned findings of malignancies in rodents.For Denmark's Novo Nordisk, whose shares fell nearly 4 percent on Friday, the issue is something of a two-edged sword, according to Sam Fazeli of Piper Jaffray.Novo could potentially gain from problems at its rival, and it might also benefit from any shift in demand toward its short-acting insulins.
But there is a risk that users will be wary of all modern insulins and there may be a more general switch to older, cheaper insulin products.($1=.7177 Euro)(Editing by Jon Loades-Carter) Deals baseball managers . More information can be found online at SentrySentry Data Systems, Inc baseball tickets . offers healthcare business intelligence technologysolutions that address a variety of operational, workflow, compliance, andfinancial challenges found within hospitals and pharmacies brandon phillips jerseys . These productsinclude the hospital pharmacy management application Sentinel RCM(TM) (RevenueCycle Manager), pharmacy transaction processing platform Sentrex(TM), and thehealthcare business intelligence application HealthBIT(TM) (BusinessIntelligence Technology) . These tools run on top of Sentry's healthcare cloudcomputing platform, Datanex(TM), which is available to independent softwaredevelopers and other healthcare entities.Headquartered in Deerfield Beach, FL, Sentry Data Systems, Inc. currentlyserves clients in over 30 states and its systems process millions ofhealthcare transactions per day. More information can be found online at .NOTE: Sentinel RCM, Sentrex, HealthBIT, Datanex, Claims Guardian and anyadditional Sentry marks herein are trademarks of Sentry Data Systems, Inc.Product specifications subject to change at any time without prior notice (C)Sentry Data Systems, Inc.
Comments are closed.